Market News & Trends
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 From Phase 1/2 BRILLIANCE Trial
Editas Medicine, Inc. recently announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101, an in vivo CRISPR/Cas9 genome editing medicine in a company-sponsored…
Meridian Medical Technologies & Kindeva Drug Delivery to Combine
Meridian Medical Technologies recently announced it will combine with Kindeva Drug Delivery to create a leading global drug-device combination product Contract Development and….
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunities….
Monopar Announces Encouraging Clinical Data From Ongoing Camsirubicin Phase 1b Trial
Monopar Therapeutics Inc. recently released encouraging data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft tissue sarcoma patients. The data…
Key Patent Issued on Eligo’s Gene-Editing Breakthroughs Applied to Skin Disorders
Eligo Bioscience recently announced the issuance by the USPTO of the first patent in a wide family covering genetic engineering of a key skin microbiome species, Cutibacterium acnes, to support….
Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
Daré Bioscience, Inc. recently announced it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support activities related to development…
ExCellThera Announces Completion of Phase 2 clinical Trials for UM171-Expanded Cell Therapy in High-Risk Blood Cancers
ExCellThera Inc. recently announced the completion of patient enrollment in its initial Phase 2 studies for high-risk leukemias and myelodysplastic syndromes (MDS). ECT-001 Cell Therapy,…
Indivior PLC to Acquire Opiant Pharmaceuticals
Opiant Pharmaceuticals Inc. recently announced it has entered into a definitive merger agreement to be acquired by Indivior Inc, a subsidiary of Indivior PLC (LON: INDV). Under the terms of the agreement,….
Tjoapack Strengthens its Injectables Offering With Addition of Prefilled Syringes Assembly & Packaging Services
Global pharmaceutical contract packaging organization (CPO), Tjoapack has invested in a new high-speed packaging line for prefilled syringes and vials at its production facilities in…
IMUNON Enters Technology Evaluation Agreement With Acuitas to Evaluate Placcine Plasmid DNA With Lipid Nanoparticle Delivery System
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid vaccine platform as an alternative to mRNA and protein vaccines….
Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA
Akari Therapeutics, Plc recently announced the US FDA has granted the Rare Pediatric Disease Designation to nomacopan for the treatment of pediatric hematopoietic stem cell…
Minoryx & Neuraxpharm Announce Strategic Alliance to Provide New Therapy for Rare CNS Disease
The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD)….
Evonik Wins Pharma Award for Polymer-Based Technology for mRNA Delivery
Evonik Health Care has won the prestigious CPHI Excellence in Pharma Award in the category Packaging and Drug Delivery. The winning innovation is a new…
Immutep Granted New Patents for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
Immutep Limited recently announced the grant of two new patents (Nos. 7160345 and 10-2441425) titled Combined Preparations for the Treatment of Cancer by the Japanese Patent…
Ocuphire Pharma Enters Global License Agreement for Development & Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia & Night Vision Disturbances
Ocuphire Pharma, Inc. recently announced it has concluded an exclusive license agreement with FamyGen Life Sciences, Inc. for the development and commercialization of Nyxol across…
Insilico Medicine Signs Strategic Research Collaboration With Sanofi Worth up to $1.2 Billion
Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up to 6 targets, and additional R&D and sales milestones plus tier-based mid-single to low double-digit royalties….
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE (setmelanotide) in Bardet-Biedl Syndrome
Rhythm Pharmaceuticals, Inc. recently announced that previously disclosed results from a Phase 3 clinical trial that evaluated IMCIVREE (setmelanotide), an MC4R agonist, in patients with…
Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial
Achieve Life Sciences, Inc. recently announced target enrollment has been reached in the Phase 2 ORCA-V1 clinical trial. ORCA-V1 is evaluating the efficacy and safety…
SomaLogic Teams With Molecular Genomics to Bring the 7,000-Plex SomaScan Platform to Asia
SomaLogic, Inc. recently announced Singapore-based Molecular Genomics will be the first site in Asia to offer the 7,000-plex SomaScan Assay and provide SomaScan data to…
GHO Capital & The Vistria Group to Acquire Alcami From Madison Dearborn Partners & Ampersand Capital Partners
Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, and The Vistria Group, a middle-market private investment firm focused on delivering financial returns and societal impact, recently….
